News

Chris Oviatt is a golfer from Oregon who was diagnosed with Charcot-Marie-Tooth disease (CMT) in 1987. As she prepares for the US Adaptive Open in Kansas, Chris took time to chat with CMTA’s CEO Dr. Sue Bruhn about her journey ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded the CMTA Center of Excellence ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of David Skarinsky to its Strategy to ...

The Charcot-Marie-Tooth Association (CMTA) is excited to share that our Alliance Partner, NMD Pharma, has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase II clinical trial for their investigational drug, NMD670, in patients with ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $240K into a new gene replacement therapy for CMT4A, with a potential to translate to other ...